Dimed Distribuidora de Medicamentos (BSP:PNVL3) Altman Z2-Score: 2.87 (As of Jul. 03, 2026) — Near Median


BSP:PNVL3 Dimed SA Distribuidora de Medicamentos BSP:PNVL3
89 GF Score
Price R$10.87
GF Value R$13.54
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Dimed Distribuidora de Medicamentos Altman Z2-Score?

Dimed Distribuidora de Medicamentos BSP:PNVL3 +0.37% 89 Altman Z2-Score is 2.87 as of Jul. 03, 2026, which is 2% below its 10-year median of 2.92. GuruFocus rates BSP:PNVL3 with a GF Score™ of 89/100 and a GF Value™ of R$13.54 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 996 Drug Manufacturers companies, Dimed Distribuidora de Medicamentos ranks worse than 58.94% on this metric.

Altman Z2-Score, also known as Z"-Score, is used to predict the likelihood that a non-manufacturing company (excluding property/financial company) will face bankruptcy within a two-year period.

Good Sign:

Dimed Distribuidora de Medicamentos has a Altman Z2-Score of 2.87, indicating it is in Safe Zones. This implies the Altman Z2-Score is strong.

The zones of discrimination were as such:

When Altman Z2-Score <= 1.1, it is in Distress Zones.
When Altman Z2-Score >= 2.6, it is in Safe Zones.
When Altman Z2-Score is between 1.1 and 2.6, it is in Grey Zones.

The historical rank and industry rank for Dimed Distribuidora de Medicamentos's Altman Z2-Score or its related term are showing as below:

BSP:PNVL3' s Altman Z2-Score Range Over the Past 10 Years
Min: 2.31   Med: 2.92   Max: 3.93
Current: 2.87

During the past 13 years, Dimed Distribuidora de Medicamentos's highest Altman Z2-Score was 3.93. The lowest was 2.31. And the median was 2.92.


Dimed Distribuidora de Medicamentos  (BSP:PNVL3) Altman Z2-Score Explanation

The original Z-Score model was based on publicly traded manufacturing companies while the Z2-Score, also known as Z"-score can be used for any type of company excluding property/financial companies. Both Z-Score and Z2-Score describes the financial health of a company, and its likelihood of financial distress.

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4_2, Net Worth (Total Stockholders Equity - Preferred Stock)/Total Liabilities (NW/TL): it compares a company’s stock net worth with its total liabilities and can be used to assess the extent of its reliance on debt.

Read more about Altman Z2-Score, the original research on Z-Score and the additional research on Z2-Score.


Be Aware

Altman Z2-Score does not apply to financial companies.


Dimed Distribuidora de Medicamentos Altman Z2-Score Related Terms


Dimed Distribuidora de Medicamentos Altman Z2-Score Historical Data

* Premium members only.

The historical data trend for Dimed Distribuidora de Medicamentos's Altman Z2-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Dimed Distribuidora de Medicamentos Altman Z2-Score Chart

Dimed Distribuidora de Medicamentos Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Altman Z2-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.77 2.41 2.59 2.66 2.70

Dimed Distribuidora de Medicamentos Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Altman Z2-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.93 2.79 2.99 2.70 2.87

BSP:PNVL3 vs LLY, JNJ, ABBV: Altman Z2-Score Comparison

For the Drug Manufacturers - General subindustry, Dimed Distribuidora de Medicamentos's Altman Z2-Score, along with its competitors' market caps and Altman Z2-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Dimed Distribuidora de Medicamentos Altman Z2-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Dimed Distribuidora de Medicamentos's Altman Z2-Score distribution charts can be found below:

* The bar in red indicates where Dimed Distribuidora de Medicamentos's Altman Z2-Score falls into.


BSP:PNVL3
89GF Score
Dimed SA Distribuidora de Medicamentos BSP:PNVL3
Altman Z2-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Dimed Distribuidora de Medicamentos Altman Z2-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

Z2-Score, also known as Z"-Score is the Z-Score for non-manufacturing companies excluding property/financial companies.

Dimed Distribuidora de Medicamentos's Altman Z2-Score for today is calculated with this formula:

Z=6.56*X1+3.26*X2+6.72*X3+1.05*X4_2
=6.56*0.2624+3.26*0.0055+6.72*0.0825+1.05*0.5502
=2.87

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z2-Score when X4_2 value is 0.

Trailing Twelve Months (TTM) ended in Mar. 2026:
Total Assets was R$3,664 Mil.
Total Current Assets was R$2,145 Mil.
Total Current Liabilities was R$1,184 Mil.
Retained Earnings was R$20 Mil.
Pre-Tax Income was 37.176 + 46.888 + 41.774 + 27.606 = R$153 Mil.
Interest Expense was -39.926 + -38.481 + -40.092 + -30.364 = R$-149 Mil.
Total Liabilities was R$2,363 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(2145.465 - 1184.327)/3663.514
=0.2624

X2=Retained Earnings/Total Assets
=20.231/3663.514
=0.0055

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(153.444 - -148.863)/3663.514
=0.0825

X4_2=Net Worth/Total Liabilities
=(Total Stockholders Equity - Preferred Stock)/Total Liabilities
=(1300.273 - 0)/2363.241
=0.5502

The zones of discrimination were as such:

Distress Zones - 1.1 < Grey Zones < 2.6 - Safe Zones

Dimed Distribuidora de Medicamentos has a Altman Z2-Score of 2.87 indicating it is in Safe Zones.

Frequently Asked Questions Learn more about Altman Z2-Score →
What does a Altman Z2-Score of 2.87 mean?
Dimed Distribuidora de Medicamentos (BSP:PNVL3) has a Altman Z2-Score of 2.87 as of Jul. 03, 2026. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on Dimed Distribuidora de Medicamentos and its competitors. This is near median its historical median of 2.92. Over the past decade, Dimed Distribuidora de Medicamentos' Altman Z2-Score has ranged from 2.31 to 3.93. According to the industry distribution chart, Dimed Distribuidora de Medicamentos ranks #587 out of 996 companies in the Drug Manufacturers industry, placing it in the top 58.9%.
Is Dimed Distribuidora de Medicamentos' Altman Z2-Score too high?
Dimed Distribuidora de Medicamentos' current Altman Z2-Score of 2.87 is near median its 10-year median of 2.92. Over the past 10 years, this metric has ranged from a low of 2.31 to a high of 3.93. The Drug Manufacturers industry median Altman Z2-Score is 3.87. Dimed Distribuidora de Medicamentos' value of 2.87 is 25.7% below this industry median. Based on the distribution chart, Dimed Distribuidora de Medicamentos ranks #587 out of 996 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Dimed Distribuidora de Medicamentos has a GF Score™ of 89/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Dimed Distribuidora de Medicamentos' Altman Z2-Score compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Dimed Distribuidora de Medicamentos ranks #587 out of 996 companies for Altman Z2-Score. This places Dimed Distribuidora de Medicamentos in the lower half of its industry. The industry median Altman Z2-Score is 3.87. Dimed Distribuidora de Medicamentos' value of 2.87 is 25.7% below this benchmark. Historically, Dimed Distribuidora de Medicamentos' own Altman Z2-Score has ranged from 2.31 to 3.93 over the past decade. While the company's 10-year median is 2.92 vs. the industry median of 3.87, Dimed Distribuidora de Medicamentos has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z2-Score for a Drug Manufacturers company?
The median Altman Z2-Score among Drug Manufacturers companies is 3.87, based on 996 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z2-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z2-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Dimed Distribuidora de Medicamentos's current Altman Z2-Score of 2.87 is 25.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z2-Score mean?
A high Altman Z2-Score can signal that a stock is expensive relative to its fundamentals. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on Dimed Distribuidora de Medicamentos and its competitors. For the Drug Manufacturers industry, the median Altman Z2-Score is 3.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dimed Distribuidora de Medicamentos's current Altman Z2-Score is 2.87, which is near median its own 10-year median of 2.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dimed Distribuidora de Medicamentos stock overvalued right now?
Based on GuruFocus' analysis, Dimed Distribuidora de Medicamentos (BSP:PNVL3) is currently considered Modestly Undervalued. The stock's GF Value™ is R$13.54, compared to a current price of R$10.87 — trading 19.7% below its estimated fair value. The current Altman Z2-Score is 2.87, which is near median its 10-year median of 2.92 and 25.7% below the Drug Manufacturers industry median of 3.87. Dimed Distribuidora de Medicamentos' overall GF Score™ is 89/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z2-Score calculated?
Altman Z2-Score is calculated from a company's financial statements. For Dimed Distribuidora de Medicamentos (BSP:PNVL3), the current Altman Z2-Score is 2.87 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Dimed Distribuidora de Medicamentos (BSP:PNVL3) Overvalued in 2026?

Based on GuruFocus' analysis, Dimed Distribuidora de Medicamentos stock appears to be undervalued. The current stock price of R$10.87 is trading 19.7% below its estimated GF Value™ of R$13.54. GuruFocus considers Dimed Distribuidora de Medicamentos to be Modestly Undervalued.

Key valuation signals for BSP:PNVL3:

  • Altman Z2-Score: 2.87 (near median its 10-year median of 2.92)
  • GF Value™: R$13.54 vs. price of R$10.87 (19.7% below fair value)
  • GF Score™: 89/100 with 5 warning signs
  • Industry Position: 25.7% below the Drug Manufacturers median (#587 of 996)

No single metric tells the full story. See the BSP:PNVL3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Dimed Distribuidora de Medicamentos Business Description

Address Avenida Industrial Belgraf, 865, Eldorado do Sul, RS, BRA, 92990-000
Dimed SA Distribuidora de Medicamentos is engaged in the sale of medicines, perfumery, personal care and beauty products, cosmetics and dermocosmetics. It has single reportable segment that is, The Retail segment. The Retail segment has 556 stores that sell more than 15,000 items among drugs and personal care and beauty products. In addition to adding divisions of cosmetics, drugs and food, Lifar is responsible for the production of brands in Brazil, as well as products of its own brand Panvel.
89GF Score

Get the complete analysis for BSP:PNVL3

Altman Z2-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

R$10.87
Price
R$13.54
GF Value